Mallinckrodt off premarket on FDA reclassification

• Mallinckrodt (NYSE:MNK) is down 8% premarket on average volume in response to the FDA's reclassification of its generic ADHD med.
• Previously: FDA downgrades classification of Mallinckrodt's ADHD med